Skip to main content

Lupus

      RT @DrCassySims: What has changed since the 2020 @ACRheum #reproductive guidelines?

      Abstract #1717 425 SLE/RA patients
      What has changed since the 2020 @ACRheum #reproductive guidelines? Abstract #1717 425 SLE/RA patients: 📍 significant improvement in pre-#pregnancy counseling and discussions in reproductive goals 📍No improvements in birth control use or documentation
      RT @KDAO2011: #RheumPearls: Check APLs in all SLE pts because they influences contraceptive choice, postpartum/surgery a
      2 years ago
      #RheumPearls: Check APLs in all SLE pts because they influences contraceptive choice, postpartum/surgery anticoag prophylx, and HRT counseling Dr. J Kolfenbach #ACR22 @rheumnow https://t.co/Hnrh4NhmBj
      The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…
      RT @RHEUMarampa: P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flare
      2 years ago
      P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares 📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL 📌Non-adj: antidsDNA+, antiSm+ addt'l predictors 🧐p alb & antiSm+ potential predictors? #ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe
      Women with systemic lupus erythematosus (SLE) face unique reproductive challenges including increased risk of thrombosis with estrogen-containing contraceptives, preeclampsia, pregnancy loss, and…
      Systemic lupus erythematosus (SLE) is a chronic autoimmune condition and monitoring disease activity is an important aspect of disease management.  The anti-dsDNA antibody is highly specific for…
      RT @EBRheum: Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless!

      It's not flashy but
      2 years ago
      Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless! It's not flashy but it winds up being the backbone/foundation for many subsequent studies Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD #ACR22 @RheumNow https://t.co/64z7DBFCnX
      RT @ericdeinmd: Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
      BEL: lower risk of severe ifn (HR 0.81) and hospital
      2 years ago
      Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr